BiotechTube

Benralizumab + 129 Xenon

Pre-clinicalActive
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma; Eosinophilic

Conditions

Asthma; Eosinophilic

Trial Timeline

Mar 1, 2022 โ†’ Dec 1, 2026

NCT ID
NCT03733535

About Benralizumab + 129 Xenon

Benralizumab + 129 Xenon is a pre-clinical stage product being developed by AstraZeneca for Asthma; Eosinophilic. The current trial status is active. This product is registered under clinical trial identifier NCT03733535. Target conditions include Asthma; Eosinophilic.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT03733535Pre-clinicalActive

Competing Products

20 competing products in Asthma; Eosinophilic

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
77
DuleraMerckApproved
85
BriquilimabJasper TherapeuticsPhase 1
25
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
52
RoflumilastAstraZenecaPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
52
Regadenoson + PlaceboAstellas PharmaApproved
85
TacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 2
52
Zero-dose + 90 mcg of PROAIRยฎ HFA + 180 mcg of 90 mcg of PROAIRยฎ HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
77
rabeprazoleEisaiPhase 3
77
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
52
Placebo + BrodalumabKyowa KirinPhase 2
52
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
52
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
77
Budesonide 80 ฮผg and Formoterol Fumarate Dihydrate 4.5 ฮผg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
77

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85